A 2012 study conducted in France has rekindled the controversy, reporting that patients with idiopathic GH deficiency and idiopathic or gestational short stature who were treated with recombinant hGH during childhood were at a small increased risk of death when compared with individuals in the general French population [54]. Here, GH1 is linked to short stature due to GHSR deficiency.